> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Sol-Gel Has $45.7 Million To Fund Development Into Early 2028, It Expects
- URL: https://www.bullished.co/sol-gel-has-45-7-million-to-fund-development-into-early-2028-it-expects-5bdd0873/
- Published: 2026-11-12T13:40:59.000Z
- Updated: 2026-11-12T13:40:59.000Z
- Description: The skin-drug developer expects late-November trial results and intends to retain U.S. rights if its lead treatment wins approval.
- Author: Matteo Parrino
- Tags: SEC Filings, SLGL, Industry: Healthcare

[Sol-Gel Technologies](https://www.bullished.co/tag/slgl/), which is testing a gel to prevent skin tumors in patients with Gorlin syndrome, reported [$45.7 million](https://www.sec.gov/Archives/edgar/data/1684693/000117891326005177/exhibit%5F99-1.htm?ref=bullished.co) in September-end cash resources in Thursday's results release. The company expects that funding to cover its requirements into the first quarter of 2028, with initial results from its lead trial expected in late November 2026.

## Trial Spending Eases

The funding consists of $31.3 million in marketable securities and $14.4 million in cash, cash equivalents and deposits.

Third-quarter research and development spending fell to $5.1 million from $5.7 million a year earlier. Sol-Gel attributed the decline mainly to lower trial costs for SGT-610, its investigational patidegib gel. General and administrative expenses were $1 million in both periods.

The quarterly net loss narrowed to $5.6 million from $5.9 million. Basic and diluted loss per ordinary share was $1.72, compared with $2.13, while revenue fell to $41,000 from $400,000.

The longer reporting period showed a different direction: the net loss for the first nine months widened to $13 million from $3.1 million a year earlier. Revenue for that period fell to $740,000 from $18.7 million.

## A Test Of Tumor Prevention

SGT-610 is being tested to prevent new basal cell carcinomas, a form of skin cancer, in adults with Gorlin syndrome, a rare genetic disease. Sol-Gel announced in September that scheduled patient visits had ended; 102 of 113 participants completed the late-stage study, approximately 90%.

The trial's main goal is to measure new facial tumors after 12 months of twice-daily treatment. It also measures new tumors eligible for surgery. Participants were randomly assigned, and the study compared the treatment with its gel vehicle under blinded conditions.

Mori Arkin, Sol-Gel's executive chairman, said the completion rate was "[exceeding our original](https://www.sec.gov/Archives/edgar/data/1684693/000117891326005177/exhibit%5F99-1.htm?ref=bullished.co) expectations for patient retention."

At an October 14 investor event in New York, Ervin Epstein Jr. of Alta Bates Summit Medical Center, Kavita Sarin of Stanford Cancer Institute, Elizabeth M. Billingsley of Penn State College of Medicine and Julie Breneiser of the Gorlin Syndrome Alliance discussed the disease's burden. Topics included limitations of surgery and off-label systemic treatment, and whether tumor prevention could reduce repeated operations.

## Keeping The U.S. Rights

Sol-Gel intends to keep all U.S. commercial rights to SGT-610 if it wins approval. Its planned model combines an outside commercialization organization with a small sales team serving physicians who treat Gorlin syndrome. Planning covers distribution, patient support, market access and medical affairs.

The company already developed FDA-approved creams Twyneo for acne and Epsolay for rosacea. It sold their U.S. rights to Mayne in April 2025 and has licensing and commercialization agreements with Searchlight in Canada and Beimei in China and other Asian markets, plus agreements covering most European countries, South Africa and South Korea.

Beyond Gorlin syndrome, Sol-Gel is pursuing patidegib studies announced in August for use before Mohs surgery and prevention of frequently recurring basal cell carcinomas. It is also evaluating an injectable treatment for jaw cysts associated with Gorlin syndrome and advancing the investigational topical treatment SGT-210.

The next clinical milestone is the initial Gorlin syndrome trial readout expected in late November. Sol-Gel's path toward an approval application and commercialization depends on positive clinical results.

### Sources

- [Form 6-K — U.S. commercial readiness activities for SGT-610 continue to advance ahead of a potential regulatory submission and launch NESS](https://www.sec.gov/Archives/edgar/data/1684693/000117891326005177/exhibit%5F99-1.htm?ref=bullished.co) — SEC EDGAR

### More on Sol-Gel Technologies

- [Atlanta Biotech Fund Trails Edge Takes 5.1% Of Sol-Gel, Calls Stake Passive](https://www.bullished.co/atlanta-biotech-fund-trails-edge-takes-5-1-of-sol-gel-calls-stake-passive-6d613a13/)

[All Sol-Gel Technologies (SLGL) coverage →](https://www.bullished.co/tag/slgl/)